ライフサイエンスコーパス: overactive bladder

1 ment of refractory detrusor overactivity and overactive bladder.

2 involved in the management of patients with overactive bladder.

3 ecent developments in pharmacotherapy of the overactive bladder.

4 ted pig bladder strips, an in vitro model of overactive bladder.

5 evere lower urinary tract symptoms including overactive bladder.

6 and are obvious targets for treatment of the overactive bladder.

7 openers may have utility in the treatment of overactive bladder.

8 sorders of urine storage and voiding such as overactive bladder.

9 Overactive bladder affects 10-12% of men, of which 13% a

10 Overactive bladder affects 10-27% of men, a significant

11 on is required to identify the true cause of overactive bladder, allowing new targeted treatments to

12 -five urine specimens (from 41 patients with overactive bladder and 24 controls) were examined using

13 drugs remain the first-line treatment of the overactive bladder and a favorable efficacy/tolerability

14 dysfunctional voiding, Botox injections for overactive bladder and an adult anticholinergic for over

15 Overactive bladder and benign prostatic hyperplasia comm

16 Control patients did not have overactive bladder and did not have a clinically relevan

17 cantly less likely to receive a diagnosis of overactive bladder and more likely to receive a diagnosi

18 Men with overactive bladder and other lower urinary tract symptom

19 nation with an alpha-blocker, in men with an overactive bladder and summarize the efficacy and safety

20 d clinical trials, to establish the cause of overactive bladder and to determine the best method of m

21 ndicate that BK channel dysfunction leads to overactive bladder and urinary incontinence.

22 ure drug targets for effective management of overactive bladder are discussed.

23 may be a viable target for the treatment of overactive bladder disorders.

24 from urothelium results in incontinence and overactive bladder due to abnormal mechanotransduction;

25 ere are persistent urinary storage symptoms (overactive bladder) following therapy with an alpha-bloc

26 New theories and modified definitions of overactive bladder have been proposed, structured eviden

27 Present treatments for overactive bladders have significant non-compliance rate

28 r existing anticholinergics, in treating the overactive bladder in children need closer scrutiny.

29 l nerve neuromodulation for the treatment of overactive bladder in patients who do not respond to opt

30 The overactive bladder is a common and distressing condition

31 Overactive bladder is an important lower urinary tract s

32 Overactive bladder is now recognized as a chronic debili

33 ur understanding of the basic science of the overactive bladder it is becoming clear that the control

34 However, coexisting overactive bladder may be responsible for storage sympto

35 As overactive bladder (OAB) is a prevalent and chronic medi

36 human beta3-AR agonist for the treatment of overactive bladder (OAB), is described.

37 tor agonists (beta3-AR) for the treatment of overactive bladder (OAB).

38 al treatment of men with incontinence due to overactive bladder or to stress urinary incontinence pub

39 veral potential targets for treatment of the overactive bladder, particularly within the mechanosenso

40 on the Urogenital Distress Inventory and the Overactive Bladder Questionnaire (both P <0.001) at both

41 both before and after RTx as measured by the Overactive Bladder Questionnaire and International Prost

42 nd 2010 were asked to complete the validated Overactive Bladder Questionnaire based on patient sympto

43 inumtoxinA showed greater improvement in the Overactive Bladder Questionnaire SF for symptom bother (

44 om baseline in urinary symptom scores in the Overactive Bladder Questionnaire Short Form (SF); range,

45 00, higher scores indicating worse symptoms; Overactive Bladder Satisfaction questionnaire; range, 0-

46 dies using anticholinergics in patients with overactive bladders supports these findings.

47 rusor instability with subsequent obstructed/overactive bladder symptom complexes not dissimilar to t

48 y, inhibit detrusor overactivity and resolve overactive bladder symptoms acutely.

49 Men with enlarged prostates experience overactive bladder symptoms of urgency and frequency.

50 hat in men with persistent storage symptoms (overactive bladder symptoms), clinically meaningful impr

51 ht be useful clinically for the treatment of overactive bladder symptoms.

52 ection and a control group the prevalence of overactive bladder syndrome (OAB), and how it was associ

53 Lower urinary tract disorders such as overactive bladder syndrome (OABS) and interstitial cyst

54 Overactive bladder syndrome (OBS) results from disturban

55 gastroesophageal reflux disease (GERD), and overactive bladder syndrome (OBS), as well as other gast

56 apy of lower urinary tract disorders such as overactive bladder syndrome and cystitis.

57 ower urinary tract storage disorders such as overactive bladder syndrome and urinary incontinence sig

58 lower urinary tract symptoms, including the overactive bladder syndrome, and that combination of the

59 tment of nonobstructed urinary retention and overactive bladder syndrome, especially when accompanied

60 ifenacin, as a treatment alternative of male overactive bladder syndrome.

61 treatment of obstructive airway disease and overactive bladder syndrome.

62 he treatment of lower urinary tract symptoms/overactive bladder syndrome/and detrusor overactivity.

63 ive bladder and an adult anticholinergic for overactive bladder that underwent testing in children; e

64 tion and therefore are candidate targets for overactive bladder therapy.

65 oms and nonobstructive pattern recognized as overactive bladder type has also been successfully evalu

66 actions is pivotal to the disease process in overactive bladder, urge incontinence, and spinal cord i

67 Treatment options for the overactive bladder were recently discussed at the 4th In

68 This mix of obstructed, overactive bladder with hidden stress incontinence incre